Nicholas Piramal: Lifestyle segment thrust - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Nicholas Piramal: Lifestyle segment thrust

Jun 12, 2003

Nicholas Piramal India Limited (NPIL) has reported a healthy growth in topline for FY03 while its bottomline has grown at a more robust rate. In its results announced for FY03, the company has reported a 11% growth in topline while its bottomline has improved by 145%. Improvement in the company's performance in FY03 was mainly on account of better operating margins and lower interest expenses.

(Rs m)FY02FY03Change
Net Sales 8,662 9,642 11.3%
Other Income 374 506 35.2%
Expenditure 7,378 7,863 6.6%
Operating Profit (EBDIT) 1,284 1,779 38.5%
Operating Profit Margin (%)14.8%18.5%
Interest 320 206 -35.7%
Depreciation 169 235 39.1%
Profit before Tax1,1701,84457.7%
Extraordinary items (442) (600)
Tax 245 63 -74.2%
Profit after Tax/(Loss) 482 1,181 144.9%
Net profit margin (%)5.6%12.3%
No. of Shares 38.0 38.0
Diluted Earnings per share* (Rs)12.731.1
P/E Ratio (x) 9.4
(* annualised)

NPIL has seen strong growth (20%) in its core business of formulations. NPIL has indicated that due to its focus on the lifestyle segment, it has been able to grow faster than the industry average of 6% in the formulations segment. Its acquisition of the ICI's pharma business has helped it further in increasing its exposure to the lifestyle segment. NPIL acquired ICI Limited's pharmaceutical business in FY02. However since this acquisition was done on 26th March 2002, the full effect of the acquisition was seen in FY03.

The company also acquired Global Bulk Drugs & Fine Chemicals, in FY03. Global Bulk Drugs & Fine Chemicals produces active pharmaceutical ingredients (APIs) and intermediaries and has strong demand for its products in the US and the western European market. ICI Limited on the other hand has a strong exposure to cardiovascular and anaesthetic therapeutic segment. The company also has significant export presence for its bulk drug business. NPIL's growth in topline has also been fueled to an extent by growth in its export revenues. Exports as a percentage of total revenues now stand at 3.4% compared to a negligible amount in FY02.

The company has also significantly improved its operating margins in FY03. The improvement is to the tune of 370 basis points. This improvement was mainly on account of fall in other expenses. Other expenses as a percentage of total revenues have fallen to 23% compared to 27% in FY02. The company has also significantly benefited from a low interest rate regime. The company has managed to reduce its interest expenses by 35% in FY03. This has improved profitability significantly.

NPIL's acquisitions in FY03 have resulted in an increase in its depreciation expenses. Depreciation has gone up by 39% in FY03. However the company has seen significant benefits from its acquisition of Global Bulk Drugs & Fine Chemicals. NPIL got a tax benefit of Rs 265 m due to its acquisition. Profit growth however has been restricted due to extraordinary expenses to the tune of Rs 600m, which was mainly comprised of VRS expenses.

The stock, at Rs 291, is trading at a P/E multiple of 9x its FY03 earnings. The company seems to have benefited from its acquisitions made in the past and recently. Acquisitions have helped it enter into the lucrative and fast growing lifestyle therapeutic segment. Going forward, the company is likely to see growth in its topline from its inorganic growth initiatives and strong growth from its new products in the lifestyle segment. Profitability is also expected to improve due to rationalisation of interest costs and better operating margins.

Equitymaster requests your view! Post a comment on "Nicholas Piramal: Lifestyle segment thrust". Click here!


More Views on News

PIRAMAL ENTERPRISES Share Price Up by 5%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Apr 13, 2021 | Updated on Apr 13, 2021

PIRAMAL ENTERPRISES share price is trading up by 5% and its current market price is Rs 1,712. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index is PIRAMAL ENTERPRISES (up 5.0%). The top losers are LUPIN (down 0.3%) and ABBOTT INDIA (down 0.3%).

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This... (Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Apr 13, 2021 03:38 PM


  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks